Discrepancies in Moderna’s FDA (Vaccine) Report Demand Answers

No votes yet

Search the scientific literature for examples of long-term vaccine randomized clinical trials that use inert placebos — you will not find them. Short-term studies are the preferred mode of vaccine manufacturers — even when there is no emergency — leaving long-term vaccine safety to be assessed after the vaccine goes to market.

The public is never afforded the opportunity to opt out of human subject trials in spite of federal regulations that provide protections against experimentation — with special protections for children and pregnant women.

Moderna’s mRNA vaccine is touted as having great promise for use against SARS-CoV-2, the virus that causes coronavirus. As a new technology, it has features that make it competitive.

First, the design allows rapid updates of the vaccine to match new circulating types of virus. This is a stark contrast to, say, Merck’s MMR vaccine, which is showing signs of waning usefulness, not at all unexpected — in fact predicted to be obsolete in 2022 — unless updated to match the wild measles virus every two years or so.